Information Provided By: 
Fly News Breaks for July 7, 2016
DXCM
Jul 7, 2016 | 07:56 EDT
Ahead of the FDA panel meeting to assess a potential dosing claim for Dexcom's G5 505 software algorithm, Leerink analyst Danielle Antalffy expects the panel to be positive given the accuracy of its device and clinician and industry support. However, with the company's shares up about 30% since mid-May, the analyst says the risk/reward heading into this event is now less favorable. Antalffy reiterates an Outperform rating on the shares, given her expectation for "consistent" beat and raise quarters ahead.
News For DXCM From the Last 2 Days
DXCM
Apr 25, 2024 | 16:05 EDT
DXCM
Apr 25, 2024 | 16:04 EDT
DXCM
Apr 25, 2024 | 15:11 EDT
Pre-earnings options volume in DexCom is 11.4x normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 5.8%, or $8.05, after results are released. Median move over the past eight quarters is 5.4%.
DXCM
Apr 25, 2024 | 13:09 EDT
